- LOGIN
- MemberShip
- 2026-05-10 01:23:41
- Company
- Omipalisib is 200 times more effective than Remdesivir
- by Kim, Jin-Gu Jul 13, 2021 11:09pm
- Attention is focusing on Omipalisib, which was newly discovered by Korean researchers as a candidate material for COVID-19. In particular, as laboratory studies show that candidate substance is more than 200 times more effective than Veklury (Remdesivir), some are optimistic that it will be a "game changer" for the corona crisis. Some pharmaceutical industries are wary of expanding interpretation of anti-virus effects. Laboratory findings do not indicate actual clinical efficacy. #Sb◆Ompalisib, new anti-cancer drug candidate for PI3K suppression mechanism KAIST and Institut Pasteur Korea announced on the 8th that they have discovered Omipalisib as a candidate material for COVID-19 treatment. The researchers explained that they explored 6,218 types of substances with a virtual drug library, and confirmed the effects of the antiviruses in seven of them. Among them, Omipalisib emphasized that "the anti-virus activity was more than 200 times higher than that of Remdesivir." Omipalisib is a drug that GSK is developing as an anti-cancer drug or an idiopathic treatment for pulmonary fibrosis. Phase I clinical trials are currently under way. It is a mechanism that inhibits "PI3K" (phosphatidylositol-3-kinase), known as cancer-causing substance. PI3K inhibitors are a new line of anti-cancer drugs that have recently attracted worldwide attention. Many global pharmaceutical companies are actively developing it. Gilead Science's Zydelig(Idelalisib), Novartis' Piqray(Alpelisib), and Bayer's Aliqopa(Copanlisib) were licensed. In addition, research and development are also in full swing in U.S. bio-ventures such as Verastem Oncology and TG Therapeutics ◆↑Interested in Nafamostat last year, failed to validate in actual clinical trials However, pharmaceutical industries are wary that laboratory results and actual effectiveness may be different. Even if clinical trials are conducted through Drug Repositioning, there is a high possibility that expected results will not come out. Institut Pasteur Korea, for example, said in May last year that it found 600 times more powerful drugs than Remdesivir through its own experiments. ▲Nafabelltan At that time, Institut Pasteur Korea explained that it conducted experiments on human lung cells by selecting drugs that could help treat COVID-19 among drugs approved by the U.S. Food and Drug Administration (FDA). The company was able to find and experiment with candidate materials in a similar way as this time. The substance that came out of this process was Nafamostat. At that time, Remdesivir was the only treatment for COVID-19, so interest in the drug, which was previously approved as a pancreatitis treatment, soared. Finally, Chong Kun-dang entered the clinical trial of Nafamostat (Nafabelltan). Chong Kun Dang conducted clinical phase II of 104 patients with severe corona in Russia. Based on this, the company filed for Conditional Marketing Authorization with the MFDS in April. However, receiving Conditional Marketing Authorization failed. Remdesivir is still the only drug developed and licensed treatment for corona through Drug Repositioning. It is a drug previously developed by Gilliard Science as an Ebola treatment.
- Company
- Dong-A ST has received the right of DA-4501 from AbbVie
- by An, Kyung-Jin Jul 13, 2021 11:08pm
- View of Dong-A ST headquarters buildingDong-A ST has received the right of MerTK inhibitor from AbbVie for the first time in five years. Dong-A ST has terminated two large technology export contracts with global pharmaceutical companies. Dong-A ST plans to review new possibilities based on joint research data that has been conducted for the past five years. Starting with biosimilar for Stelara, it is seeking new growth engines by combining its own pipeline R&D and active open innovation strategies such as diabetes and dementia. ◆AbbVie, returning rights to new drugs in five years "Not meeting internal standards" Dong-A ST announced on the 9th that it had been notified by AbbVie that it had returned the rights of the MerTK inhibitor DA-4501. The official reason for the return of rights is lack of validity. Dong-A ST explained, "We conducted a joint study on preclinical candidate materials after exporting the technology before deriving candidate materials, but the right was returned because we could not find any preclinical candidate materials satisfying AbbVie's internal standards." Dong-A ST signed a contract with AbbVie Biotechnology, a subsidiary of AbbVie, in December 2016 to transfer the global rights of MerTK inhibitor DA-4501 (excluding Korea). It is a contract worth up to $525 million, including development, approval, and milestones, in addition to $40 million in down payment that has no obligation to return. Dong-A ST received $40 million in down payment in January of the following year and recognized it in installments for 36 months. MerTK inhibitors are new mechanisms that inhibit MerTyrosine Kinase (MERTK) protein activity to help boost the immune system. Even though it was in the process of searching for candidate materials at the time, the total contract size was not only large, but also the pre-contract fee accounted for nearly 8% of the total conditions were unconventional. Industries were interested in whether pre-clinical testing would be possible, but the contract was terminated after AbbVie decided to return the rights. However, even after the termination of the contract, the down payment does not need to be refunded. ◆Donga ST, the contract for global technology export has been terminated twice. A bad relationship with Allergan This is not the first time that Dong-A ST has terminated its technology export contract with a global pharmaceutical company. Dong-A ST also received the right to develop Evogliptin, a non-alcoholic hepatitis drug, in November 2017. The acquisition of Tobira Therapheutics, the first contractor, by Allergan changed the R&D strategy. Dong-A ST's contract amount with Tobira Therapheutics in April 2016 was up to $61.5 million, including a down payment that had no obligation to return. At that time, Tobira expressed its willingness to target NASH adaptation by developing its own composites and Cenicriviroc, which was being developed in addition to Dong-A ST's single ingredient in Evogliptin, a diabetes treatment. However, Allergan is said to have decided to return the rights of Evogliptin developed by Tobira Therapheutics because it was slower than the NASH treatment developed jointly with Novartis. At the time, a Dong-A ST official said, "The decision is based on Allergan's own research and development strategy, and it has nothing to do with effectiveness or development as a treatment for Evogliptin." The recent termination of two major contracts involved Allergan. AbbVie, which notified the termination of the contract, spent a total of ₩63 billion to acquire Allergan in 2019. It is planning to make new inroads into medical aesthetic businesses such as botulinium through acquisition of Allergan. AbbVie launched a subsidiary dedicated to Allergan's cosmetic products, including Botox and filler, the following year.
- Company
- Venclexta combo in the spotlight as a new lymphoma Tx option
- by Jul 13, 2021 05:59am
- The treatment landscape for elderly patients with acute myeloid leukemia (AML), which has a 5-year relative survival rate of less than 10%, is changing with the introduction of a new drug that addresses the unmet needs and improves survival rate. AML is one of the most common types of leukemia in adults with a high unmet need in patients and HCPs alike. As one of the more aggressive types of leukemia in adults, around 140,000 new cases occur globally every year, of which around 100,000 cases end in deaths. With the same treatment being used in AML for over 40 years, not much improvement has been made in the overall survival (OS) until recently. The 5-year survival rate was at a mere 29% and was even lower for older patients. According to a study by the National Cancer Center, the relative survival rate of AML patients was very low in elderly patients - less than 10% for patients over the age of 65 and 0% for those 80 years and older. Considering that the average age of AML patients is 67 and that one-third of the patients are 75 years old, the urgency and need for an appropriate treatment was high in this respect. Also, there had been a high demand for treatment with improved efficacy and lower toxicity that can be used in older patients. Experts advised that intensive chemotherapy, the main treatment used for AML, is unsuitable in elderly patients who are likely to have comorbidities and are not generally in good condition. Venclexta combination therapy provides new opportunities for elderly AML patients The most important goal in treating AML patients is improving the overall survival period. With active R&D being conducted in the field recently, the treatment environment has improved to allow more options from combination therapy to targeted therapies to be provided according to each patient’s condition. A new treatment option is also available for the elderly patients who were not considered candidates for intensive chemotherapy. Among the new drugs that were recently introduced to the field, Abbvie’s ‘Venclexta (venetoclax)’ in combination with azacytidine, or decitabine, or low-dose cytarabine is being considered the most appropriate therapy for patients who have difficulty receiving intensive chemotherapy. Venclexta, which was approved by the Ministry of Food and Drug Safety in January, may be used in combination with azacytidine or decitabine in ‘newly-diagnosed AML adult patients aged 75 or more, or who have comorbidities that preclude the use of intensive induction chemotherapy.’ Results of the Phase III VIALE-A trial that evaluated the safety and efficacy of the Venclexta and azacitidine combination showed that the combination’s median OS was 14.7 months, 5 months longer than the 9.6 months found in the control group (placebo+ azacitidine combination). The Phase I M14-35 trial that evaluated the safety and efficacy of the Venclexta in combination with decitabine also showed that the median OS was 16.2 months. Also, the median time to first complete remission(CR) or CR with incomplete count recovery (Cri) was shorter for the Venclexta and azacitidine combination (1.3 months) than the control group (2.3 months), showing that the responses to the combination therapy occurred quickly in elderly patients as well. Also, over 60% of the patients achieved transfusion independence, raising expectations that the treatment could reduce the burden of treatment in elderly patients. Joon Ho Jang, Professor of Hematology and Oncology at the Samsung Medical Center said, “It is encouraging that a treatment that dramatically improved overall survival was introduced in the ALK treatment environment, a field where no new treatment option had been available for a long period of time. The new treatment option could provide opportunities for the difficult-to-treat patient population, such as those who are older or have comorbidities. We expect an improvement in the overall patients’ quality of life as the Venclexta+hypomethylating agent combination is effective not only in improving OS but has a short period to CR and can lower transfusion dependence. Professor Jang continued, “I hope that accessibility to these new treatment options is improved as soon as possible in consideration of the poor physical and economic conditions of patients suffering from AML in Korea."
- Company
- “Reimburse Vyndamax, the only hope for amyloidosis”
- by Eo, Yun-Ho Jul 13, 2021 05:59am
- The hATTR Patients Association came forward to call for the reimbursement approval of ‘Vyndamax’ The patient group recently delivered a ‘Statement for the insurance benefit of Vyndamax' to the Ministry of Health and Welfare and the National Health Insurance Services. The move arose among patients with the reimbursement discussions being delayed on Vyndamax (Tafamidis 61mg), which is virtually the only drug approved for the treatment of ATTR-CM (ATTR amyloidosis with cardiomyopathy). After failing to receive the essential drug designation for Vyndamzx, Pfizer, its developer, conducted a PE evaluation on its drug and applied for reimbursement again in April this year. The company hopes to receive reimbursement benefits through the Risk Sharing Agreement (RSA) scheme. However, no solid discussion or progress has been made for the drug yet. And the patients are the ones most pressed for time. ATTR-CM is a life-threatening condition with a poor treatment outcome due to a lack of treatment and is often mistaken for simple heart failure. If not treated properly, patients with ATTR-CM have a survival period of only 2 to 3.5 years. In the Phase III ATTR-ACT study, Vyndamax had reduced cardiovascular events in ATTR-CM patients and improved their functional athletic ability in the six-minute walk test, demonstrating the drug's benefit in the area with a dire need. Based on such findings, healthcare professionals in Korea are also stressing the need to prescribe Vyndamax. In the statement, the patient group said, “We ask the government to show determination for improving the treatment environment for ATTR-CM. Please help us and establish an environment where we can devote ourselves to treatment." In the ATTR-ACT study, 441 patients were randomly assigned in a 2:1:2 ratio to receive the tafamidis 80 mg dose, tafamidis 20 mg dose, or placebo, respectively. The primary endpoint of the study was the hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalizations. The key secondary endpoints were the change from baseline to month 30 for the 6-minute walk test and the score on the Kansas City Cardiomyopathy Questionnaire–Overall Summary (KCCQ-OS), in which higher scores indicate better health status. Study results showed that the tafamidis demonstrated a statistically significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo.
- Company
- Takeda's innovation in Korea
- by Eo, Yun-Ho Jul 12, 2021 06:20pm
- Moon Hee-seok, CEO of Takeda Korea Takeda Korea, which sold off OTC division & DM division, which was the company's symbol. On the occasion of the 10th anniversary of the corporation's launch, constraints have once again confirmed their commitment to pursuing innovation. Marking the 240th anniversary of Takeda Pharmaceutical's headquarters and Korea Takeda's 10th Anniversary, 'Takeda has achieved innovative growth for patients,' it held an online press conference. At this press conference, Take Korea is in line with four key treatment areas: anti-cancer, gastrointestinal disease, nervous system disease, and rare diseases.The general managers of the four major pharmaceutical businesses announced major portfolios and core strategies of each business unit. Takeda Pharmaceutical sold its DM division and OTC division to Celltrion, a South Korean company, last year. The company's Actos is a representative TZD-based drug that survived the Avandia crisis, and Whituben and Albothyl are brand OTCs that everyone knows. Takeda Pharmaceutical has prepared in advance for this change. Takeda conducted four mergers and acquisitions, including Millenium Pharmaceutical in 2008, Nycomed in 2012, ARIAD Pharmaceuticals in 2017, and Shire in 2018. Through this process, it has been strengthening major pipelines in areas such as anticancer drugs, rare diseases, and gastrointestinal diseases. It quickly responded to rapidly changing market conditions. At the press conference, Takeda announced that she would focus on the specialty care sector in line with her global strategy, signaling a more innovative drug launch.It presented a vision for the future of pharmaceuticals. Kim Jung-hun, the first speaker, introduced the "3P (Patient, People, Product)" strategy under the title "Oncology Division's 3P Strategy for Domestic Cancer Patients." The oncology division introduced solid cancer treatments Alunbrig(Brigatinib) and Zejula(Niraparib) as notable products, saying they are generating various results by prioritizing patients first. Under the theme of "Focus on Inflammatory Bowel Diseases and Fire Extinguisher Division," Kim Tae-hoon then introduced the major portfolios of the division, Kynteles(Vedolizumab) and Mezavant (Mesalazine), and he expressed his ambition to continue activities to raise awareness of the disease in the domestic market, where competition is intensifying, and to become a company specializing in treating inflammatory bowel diseases. Under the title of "Korea's Rare Genetic Disease Treatment Partnership, Genetic Disease Division," Ji Chang-deok introduced Fabri's disease treatment drugs "Replagal (Agalsidase Alfa)" and Gaucher's disease treatment "Vpriv (Velaglucerase Alfa)" to improve treatment environment in Korea. Finally, General Manager Kim Na-kyung introduced hemophilia treatments such as Adavate(Blood Coagulation Factor Ⅷ) & Adynovate(Rurioctocog Alfa Pegol) under the theme of "Pioneer in improving the domestic hemophilia treatment environment, Hemophilia treatment division." Moon Hee-seok, CEO of Takeda, said, "Takeda for the past 240 years has worked on creating an environment that can change patients' lives as treatment partners around the world with a series of passionate challenges and dedication to patients. The company, which marks the 10th anniversary of its launch in Korea this year, will once again move forward, preparing for another 10 years through patient-centered realization and innovative treatments." Takeda celebrated its 240th anniversary on June 11th. Pharmaceuticals entered the top 10 multinational pharmaceutical companies in terms of total sales in 2019 and has become a leading global bio pharmaceutical company through intensive strategies and value-based research and development for specialty care.
- Company
- Byfavo can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 12, 2021 06:19pm
- The anesthetic drug Byfavo can be prescribed at a general hospital. According to related industries, Hana Pharm's Byfavo (Remimazolam Besylate) passed DC of Big 5 general hospitals, including Seoul National University Hospital and Asan Medical Center, and will also be able to be prescribed it at major advanced general hospitals this month. Byfavo is a new anesthetic drug released more than 30 years after the approval of the general anesthetic Propofol. Launched in March, Byfavo secured manufacturing rights and exclusive sales rights from German company Paion in 2013. It has completed phase 3 of clinical trials for 198 subjects that will carry out general anesthesia in South Korea since 2018. The main indication is the induction and maintenance of general anesthesia in adults. Byfavo is a anesthetic drug that does not cause pain, and has the pharmacological advantages of conventional general anesthesia such as Propofol and Midazolam. Hana Pharm's the new Hagil plant is under construction, and expected to operate in 2023, equipped with German-made freeze-drying facilities and designed to supply Byfavo to advanced markets. The company acquired additional rights from six Southeast Asian countries to Byfavo from the original developer Germany Paion, and completed internal work to receive permission documents from these countries. Hana Pharm CEO Lee Yoon-ha said, "We are doing our best to secure supply rights in Korea and Southeast Asia, as well as in advanced markets in the future." "We are implementing strategies to enter markets by countries with a focus on partnership structure that can be supplied with expensive finished products as mid- to long-term tasks."
- Company
- Huons has secured domestic rights to Sputnik Light
- by Lee, Seok-Jun Jul 11, 2021 07:03pm
- Huons said on the 7th that it has secured exclusive rights to domestic licenses and sales of Russia's one-shot vaccine Sputnik Light. Sputnik Light will be produced from Huons Global Consortium starting from second half of this year. It was developed by Gamaleya Research Institute of Epidemiology and Microbiology. It is a one-shot vaccine that was approved for use in Russia in May. It uses the same adenovirus as Sputnik V, a double inoculation method, as a vector (transmitter. However, only one type of vector (adenovirus type 26) needs to be inoculated once. The prevention effect is 79.4% and the immune system is known to last 3 to 4 months. Since the end of February, phase III has been underway for about 7,000 people in countries such as Russia, the United Arab Emirates and Ghana. Huons is considering Emergency Use Authorization for quick domestic approval.
- Company
- Researchers find COVID-19 Txs more effective than remdesivir
- by Kim, Jin-Gu Jul 09, 2021 05:56am
- A Korean research team of the Korea Advanced Institute of Science and Technology (KAIST) discovered new drug candidates for the treatment of COVID-19. Some of the candidates are expected to have a better effect than the currently approved remdesivir (product name: Veklury). On the 8th, the joint research team of Sang-yup Lee, Distinguished Professor of Chemical & Biomolecular Engineering at KAIST, and Dr. Seung-taek Kim, researcher of Institut Pasteur Korea (IPK)’s Zoonotic Virus Laboratory announced that they have discovered potential candidates for treating COVID-19 using their virtual screening technology. The team opted for a drug repurposing strategy using virtual screening. In other words, the team sought to find substances that may help treat COVID-19 among drugs with verified efficacy and safety. The researchers first built a virtual library on 6,218 drugs that are FDA-approved or in clinical trials, and then applied their newly developed virtual screening technology. The accuracy of the system was improved by adding structural similarity and interaction similarity analysis modules to the existing docking simulation-based virtual screening technology. Summary of the COVID-19 treatment development process using virtual drug screening technology (source: KAIST) Using the platform, the team selected 38 candidate compounds that inhibit the protease and RNA-dependent RNA polymerase needed for the replication and proliferation of the COVID-19 virus. Then, the efficacy of the candidates was verified by the Institut Pasteur Korea. Testing was conducted using a monkey’s kidney cells infected with COVID-19. Of the 38 candidates, 7 compounds showed antiviral activity. The 7 compounds that showed promise were further verified on human lung cells to be narrowed down to three: omipalisib, and tipifarnib, and emodin. Among these, omipalisib was found to have an antiviral activity that is over 200 times higher than that of remdesivir. Antiviral activity of tipifarnib was found to be similar to remdesivir. Omipalisib is currently being studied in a clinical trial as a treatment for cancer and pulmonary fibrosis. Tipifarnib is being studied in a clinical as a treatment for and progeria, and emodin, which is derived from plants, is being studied in a clinical trial as an anticancer drug. The research team is planning a preclinical trial on these 3 candidate substances. In the preclinical trial, the team aims to minimize toxicity and reach the effective concentration for treating COVID-19. Regarding the findings, Professor Sang-yup Lee said, ”With the research, we were able to prepare a base technology to promptly respond to new emerging viruses. We will continue our research to develop technologies applicable to new infectious viruses as well as variants of the coronavirus.”
- Company
- Jeil's anti-cancer drug business is doing well
- by Nho, Byung Chul Jul 08, 2021 05:59am
- It is noteworthy that Jeil is investing in expanding the lineup of anticancer drugs and research and development in related fields. Jeil, who entered his 33rd year of anti-cancer drug business, has a strategic relationship with Kyowa Kirin and Taiho in Japan and is making efforts to distribute original anti-cancer drugs. When the new anti-cancer drugs were introduced in the late 1980s, Jeil established a separate anti-cancer sales and marketing team to strengthen its professional capabilities and make communication between doctors and salespeople a top priority. The most likely anti-cancer drugs are Grasin300 PFS (Kyowa Kirin), Neulasta PFS(Kyowa Kirin), UFT(Taiho), Ts-1(Taiho), and Lonsurf (Taiho). The first anti-cancer drug introduced by Jeil was UFT(Tegafur·Uracil), which was first released in Korea in 1989. It is effective in relieving symptoms such as head and neck cancer, stomach cancer, rectal cancer, liver cancer, lung cancer, prostate cancer, uterine cervical cancer, and breast cancer, etc. UFT has capsule formulations and granules, which are usually administered three to six capsules a day, and the granules are taken in two to three doses of 300 to 600 mg. In 1993, Grasin300 PFS (Filgrastim) was released. The drug, which is a granulocyte colony-stimulating factor (GCSF) preparation, has indications of neutrophilosis, bone marrow dysplasia, regenerative anemia, congenital and idiopathic neutrophilia (HIV) infections. In 2004, the company launched a treatment called Ts-1(Gimeracil, Oteracil Potassium,Tegafur) for stomach, head and neck cancer, pancreatic cancer, and non-small cell lung cancer, providing a variety of treatment options for domestic patients. In 2014, it released Neulasta (Pegfilgrastim), the second generation G-CSF and co-sold it in Korea with Kyowa Kirin. Last year, Lonsurf (Tipiracil+Trifluridine) was introduced to provide new options for colon cancer treatment, and has continued its long sales experience in the domestic anticancer drug market. Lonsurf passed DC of 50 hospitals nationwide, including Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, and Severance Hospital in the first year of its launch. Based on UBIST, it ranks first in sales in the field of oral anticancer drugs newly approved in 2020, and is recognized for its efficacy. Lonsurf is expanding its share of the colon cancer market using a specialised sales network. Attention is also focusing on Onconic therapeutics, which was established last year to improve its position in the anti-cancer drug R&D field. Bio company Onconic therapeutics is a subsidiary 100% invested by Jeil and is expected to grow as an organization focused on the development of immune and targeted anti-cancer drugs. A year after its establishment, the company announced the results of Phase 1 for PARP (Poly ADP-ribose Polymerase) and JPI-547 at ASCO, drawing attention from Big Pharma. Phase I of the clinical trial evaluated the medicinal efficacy, safety of JPI-547 in patients with terminal solid cancer, according to Lim Seok-ah, a professor of hemato-oncology at Seoul National University Hospital, announced at the poster session. It is encouraging to identify the potential as a new treatment for ovarian cancer that does not respond to existing PARP treatments. Based on the results of this Effects are expected in HRD and PARP inhibitor resistant patients, including BRCA. "Based on the 30-year history of introducing anti-cancer drugs, we are continuously expanding our specialized sales network in related fields." said a representative of Jeil. "We will strengthen the pipeline of new items and improve our long-term research and development capabilities in the anticancer drugs market through open collaboration with Onconic Therapheutics."
- Company
- Chong Kun Dang loses 1st substance patient suit on ‘Xarelto
- by Kim, Jin-Gu Jul 08, 2021 05:58am
- Pic. of Xarelto Chong Kun Dang has lost its first trial targeting the substance patent of Bayer’s new oral anticoagulant (NOAC) ‘Xarelto(rivaroxaban).’ Whether Chong Kun Dang will modify its strategy to preoccupy the market through a release of its generic before substance patent expiry due to this ruling is gaining attention. On the 6th, the Intellectual Property Trial and Appeal Board (IPTAB) has ruled in favor of the original manufacturer Bayer, in a trial to confirm the passive scope of rights for Xarelto’s substance patent that was filed by Chong Kun Dang. Chong Kun Dang had solely challenged Xarelto’s substance patent in December last year. This was interpreted as a strategy made to overtake SK Chemicals and Hanmi Pharmaceutical that is currently leading the Xarelto generic market. SK Chemicals and Hanmi Pharmaceutical were the first to succeed in avoiding Xarelto’s formulation patent. The two companies finally won in December last year after the case went up to the Supreme Court, and secured exclusive marketing approval for Xarelto's 2.5mg formulation. However, both companies were unable to overcome the substance patent, and are unable to release the generic version until Xarelto’s substance patent expires in October this year. Chong Kun Dang made the bid for victory by challenging Xarelto’s substance patent. Then, in May, the company released its Xarelto generic 'Riroxia Tab.' 15mg and 20mg' in the market, before Xarelto’s substance patent expires. This was an attempt to preoccupy the market alone by avoiding the substance patent. Chong Kun Dang’s bold attempt was considered a risky game - if the company wins the case, the early release of its generic will not have constituted a patent infringement, but if it oses, it could bring serious repercussions from patent infringement. However, Chong Kun Dang lost the first trial. Based on the current situation, it has been analyzed that Chong Kun Dang's risky attempt is highly likely to fail and that Chong Kun Dang will have to bear the burden of patent infringement. For now, Chong Kun Dang is highly likely to appeal the case, as the higher courts may decide otherwise. Some industry officials also believe that even if Chong Kun Dang loses in the end, the end results will not be bad in terms of profit or loss. An official explained, “From Chong Kun Dang’s view, the profit gained by preoccupying the market while the patent suit is reviewed by higher courts may be greater than the compensation for damages that the company will owe to Bayer from the patent infringement."
